Efficacy and safety of once-weekly bortezomib in multiple myeloma patients

Blood

Volumn 116, Issue 23, 2010, Pages 4745-4753

  Bringhen, Sara ^a   Larocca, Alessandra ^a   Rossi, Davide ^b   Cavalli, Maide ^c   Genuardi, Mariella ^a   Ria, Roberto ^d   Gentili, Silvia ^e   Patriarca, Francesca ^f   Nozzoli, Chiara ^g   Levi, Anna ^h   Guglielmelli, Tommasina ⁱ   Benevolo, Giulia ^a   Callea, Vincenzo ^j   Rizzo, Vincenzo ^k   Cangialosi, Clotilde ^l   Musto, Pellegrino ^m   De Rosa, Luca ⁿ   Liberati, Anna Marina ^o   Grasso, Mariella ^p   Falcone, Antonietta P ^q   Evangelista, Andrea ^r   Cavo, Michele ^s   Gaidano, Gianluca ^b   Boccadoro, Mario ^a   Palumbo, Antonio ^a   more..

^a MOLINETTE HOSPITAL   (Italy)

^b UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d UNIVERSITY OF BARI   (Italy)

^e OSPEDALI RIUNITI   (Italy)

^f UNIVERSITY HOSPITAL OF UDINE   (Italy)

^g CAREGGI UNIVERSITY HOSPITAL   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ SAN LUIGI GONZAGA HOSPITAL   (Italy)

^j BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^k UNIVERSITY OF MESSINA   (Italy)

^l VILLA SOFIA CERVELLO HOSPITAL   (Italy)

^m REFERRAL CANCER CENTER OF BASILICATA   (Italy)

ⁿ SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^o UNIVERSITY OF PERUGIA   (Italy)

^p S CROCE E CARLE HOSPITAL   (Italy)

^q CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^r SCDO Epidemiologia dei Tumori   (Italy)

^s UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; GABAPENTIN; MELPHALAN; NORTRIPTYLINE; PREDNISONE; THALIDOMIDE; VITAMIN;

AGED; ARTICLE; BLOOD TOXICITY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIET SUPPLEMENTATION; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 78649681350     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-294983     Document Type: Article

References (35)

1. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist. 2007;12(6):664-689.
2. San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-917.
3. Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan-prednisone versus melphalan-prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase 3 VISTA trial. J Clin Oncol. 2010;28(13):2259-2266.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (V. 2.2010). http:// www.nccn.org/professionals/physician-gls/PDF/myeloma.pdf.
5. European Medicines Agency. Velcade Summary Product Characteristics. 2009. http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000539/human-med-001130.jsp&mid=WC0b01ac058001d124&murl. Accessed September 10, 2010
6. Tariman JD, Love G, McCullagh E, Sandifer S. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs. 2008;12(3 Suppl): 29-36.
7. Mateos MV, Richardson PG, Schlag R, et al. Peripheral neuropathy with VMP resolves in the majority of patients and shows a rate plateau [abstract]. Clin Lymphoma Myeloma. 2009; 9(suppl 1):S30. Abstract A172.
8. Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009; 27(21):3518-3525.
9. Csizmadia V, Raczynski A, Csizmadia E, et al. Effect of an experimental proteasome inhibitor on the cytoskeleton, cytosolic protein turnover, and induction in the neuronal cells in vitro. Neurotoxicology. 2008;29(2):232-243.
10. Silverman L, Csizmadia V, Kadambi VJ, et al. Model for proteasome inhibition associated peripheral neuropathy [abstract 201]. Toxicol Pathol. 2006;34(7):989.
11. Silverman L, Csizmadia V, Brewer K, Simpson C, Alden C. Proteasome inhibitor associated neuropathy is mechanism based [abstract]. Blood. 2008;112(11):915a. Abstract 2646.
12. VELCADE (bortezomib) for Injection [package insert]. Prescribing information. Cambridge, MA: Millennium Pharmaceuticals Inc; 2008. Issued June 2008, Rev 9.
13. Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood. 2008;112(5):1593-1599.
14. Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol. 2006;24(19):3113-3120. (Pubitemid 46638949)
15. Richardson PG, Sonneveld P, Schuster MW, et al. Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 2009;144(6):895-903.
16. Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomibthalidomide versus bortezomib-melphalanprednisone for initial treatment of multiple myeloma: a randomised controlled trial. J Clin Oncol. In press.
17. Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467-1473.
18. National Cancer Institute. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events, Version 3.0. 9 August 2006. http:// ctep.cancer.gov/protocolDevelopment/ electronic- applications/ctc.htm#ctc-30.
19. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
20. Cox DR. Regression model and life-tables. J Roy Stat Soc B. 1972;34:187-220.
21. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18(6):695-706.
22. Gray RA. A class of k-sample test for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
23. Fine P, Gray R. A proportional hazards model for the sub-distribution of a competing risk. J Am Stat Assoc. 1999;94:496-506.
24. Mateos MV, Oriol A, Martinez J, et al. A prospective, multicenter, randomized, trial of bortezomib/melphalan/prednisone (VMP) versus bortezomib/thalidomide/prednisone (VTP) as induction therapy followed by maintenance treatment with bortezomib/thalidomide (VT) versus bortezomib/prednisone (VP) in elderly untreated patients with multiple myeloma older than 65 years [abstract]. Blood. 2009;114(22): 3a-4a. Abstract 3.
25. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594): 1209-1218.
26. Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol. 2009;27(22):3664-3670.
27. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006; 367(9513):825-831.
28. Palumbo A, Ambrosini MT, Benevolo G, et al. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood. 2007; 109(7):2767-2772.
29. Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107-3114.
30. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation- maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010;28(5):800-807.
31. Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24(27):4507-4514. (Pubitemid 46630990)
32. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol. 2007;25(28):4459-4465.
33. Palumbo A, Dimopoulos MA, Delforge M, et al. A phase III study to determine the efficacy and safety of lenalidomide in combination with melphalan and prednisone (MPR) in elderly patients with newly diagnosed multiple myeloma [abstract]. Blood. 2009;114(22):253a-254a. Abstract 613.
34. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010;116(5): 679-686.
35. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer. 2007;110(5):1042-1049. (Pubitemid 47312870)